Dear All (and with thanks to Frédéric Peyrane for leading on this newsletter): You will know that we eagerly watching the work in the EU on implementing a set of pull incentives based on use of ‘transferable data exclusivity voucher’ (TEV), also referred to as a ‘transferable exclusivity extension voucher’ (TEEV). In brief, the concept is that a TEEV
Dear All, Our colleagues in Europe have been busy! Along with yesterday’s announcement about transferrable exclusivity vouchers, we also had publication of the Horizon Europe Work Programme 2026-2027. It’s a really big program that includes within its Cluster 1 a trio of calls of interest to readers of this newsletter: HORIZON-HLTH-2027-01-DISEASE-08 call seeks projects developing
Dear All, I am pleased to learn that BARDA is holding a one-day innovation symposium on 20 Nov 2025. As you know, BARDA is a consistently creative funder of diverse medical countermeasures, including new antibiotics. For background, see these prior newsletters: 22 Jul 2025 newsletter: “BARDA RFP: Antibiotic for HABP/VABP or Bloodstream Infection” 5 Nov
Dear All, Today is a newsletter double-header! Coming hard on the heels of the opportunity to support an ESCMID petition to UNGA 2024, the UK today released the details of its next five-year action plan. Excitingly for this audience, there is an updated roadmap for the UK’s next steps in its subscription model. Here are
Dear All, I have learned that UK’s MHRA (Medicines & Healthcare products Regulatory Agency) is recruiting for the role of Chief Medical and Scientific Officer. As you would expect, the role is very senior! The person in the role will: Represent the MHRA across the medical and scientific communities Act as a senior advocate for evidence-based, effective
Dear All, BARDA has released a fascinating Sources Sought Notice (SSN) seeking data on antibacterials near, at, or beyond Phase 2. I’ve never seen one before, but an SSN is market research with which BARDA will “collect feedback from current and prospective antibiotic development partners” that will “serve as continued market research for potential future acquisitions
Dear All, Referring back to the actions planned following the 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR; 1 Oct 2024 newsletter and our dedicated UNGA 2024 webpage), you will hopefully recall the commitment to create an Independent Panel on Evidence for Action against AMR (IPEA). The broad idea is the
Dear All, Sadly, I must report that the 27th meeting of PACCARB (the US Presidential Advisory Council on Combatting Antibiotic-Resistant Bacteria) planned for 28-29 Jan 2025 has been cancelled “as the new Administration considers its plan for managing federal policy and public communications.” This 22 Jan 2025 article in the New York Times provides additional details
Dear All, D-Day and the momentous Normandy landings were 81 years ago today. In a marvelous new article on bbc.com (and with thanks to Mike Hodges for pointing it out), we can read about how “Handwritten notes reveal Churchill’s penicillin concern ahead of D-Day.” The magic of penicillin was evident … but there wasn’t enough of
Aside: Please refer to our UNGA 2024 webpage for additional post-HLM notes and updates. 28 Oct 2024 addendum and another way to get a view of the day: Hosted by Cesar Arias, Editor-in-Chief of Antimicrobial Agents and Therapy, John and Prabha Fernandes recorded a podcast discussion of the HLM. Dear All (and with thanks to Damiano